|
Tykerb addresses this problem by inhibiting both HER1 and 2 pathways.
Dr. Kent Osborne is expected to shortly start a new clinical trial using 3 drugs which inhibit all of the HER2 pathways. I will try and email him to see what the status of this trial is.
Regards
Joe
__________________
A Proud webmaster to the internet's most informed, educated, COMPASSIONATE and caring group of breast cancer survivors.
Illegitimi non carborundum
My Album
|